Last reviewed · How we verify

TAU-284

Tanabe Pharma Corporation · Phase 3 active Small molecule Under review

TAU-284 is a Tau aggregation inhibitor Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Alzheimer's disease.

Tau-284 is a tau aggregation inhibitor.

Bepotastine besilate ophthalmic solution is being studied for its safety, tolerability, and effectiveness in treating acute allergic conjunctivitis. The study, NCT00424398, is evaluating the onset and duration of action of bepotastine besilate in comparison to a placebo.

Likelihood of approval
55.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • CNS / neurology attrition -3.0pp
    CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameTAU-284
SponsorTanabe Pharma Corporation
Drug classTau aggregation inhibitor
TargetTau protein
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

Tau-284 works by binding to tau protein and preventing its aggregation, which is associated with neurodegenerative diseases such as Alzheimer's disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TAU-284

What is TAU-284?

TAU-284 is a Tau aggregation inhibitor drug developed by Tanabe Pharma Corporation, indicated for Alzheimer's disease.

How does TAU-284 work?

Tau-284 is a tau aggregation inhibitor.

What is TAU-284 used for?

TAU-284 is indicated for Alzheimer's disease.

Who makes TAU-284?

TAU-284 is developed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).

What drug class is TAU-284 in?

TAU-284 belongs to the Tau aggregation inhibitor class. See all Tau aggregation inhibitor drugs at /class/tau-aggregation-inhibitor.

What development phase is TAU-284 in?

TAU-284 is in Phase 3.

What are the side effects of TAU-284?

Common side effects of TAU-284 include Headache, Dizziness, Nausea.

What does TAU-284 target?

TAU-284 targets Tau protein and is a Tau aggregation inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing